We are pleased to welcome Naveed Shams, MD, PhD to our management team as Chief Scientific Officer. He will be leading research as well as the early clinical development of ProQR's investigational RNA therapies for inherited retinal diseases.
The ProQR family is growing fast and we spoke to the Chief Medical Officer Aniz Girach who joined ProQR in 2019. We asked him about his impression of the company after he joined, as well as the new developments he’s been working on.
It has been roughly two years since David Rodman became the Executive Vice-President Research & Development at ProQR to apply his knowledge of study design and genetic diseases on our pipeline for genetic eye diseases.